Send us a text

Health Services Research. The latest podcast by Sue Yom, MD, Editor in Chief of the International Journal of Radiation Oncology, Biology, Physics focuses on: health services research and breast cancer hypofractionation.

Send us a text

Practical Radiation Oncology section editor Daniel T. Chang, MD, hosts a conversation on the recently published ASTRO clinical practice guideline on external beam radiation therapy for primary liver cancers. Two of the guideline authors, Smith Apisarnthanarax, MD of University of Washington and Higinia Cardenes, MD, PhD of Weill Cornell, discuss the development process of the guideline and the evidence for the recommendations included.

Send us a text

National Workforce Surveys. Our Editor-in-Chief Sue Yom hosts a discussion of national workforce surveys with Dr. Shaun Loewen, Clinical Associate Professor and Director of the University of Calgary Radiation Oncology Residency Training Program and Chair of the Canadian Association of Radiation Oncology (CARO) Human Resources Committee, and Dr. Nicola Thorp, Consultant in Clinical Oncology at the Clatterbridge Cancer Centre and Honorary Consultant at the Christie Hospital, and Medical Director of Professional Practice in Clinical Oncology at the Royal College of Radiologists (RCR) in the U.K.

Send us a text

Parting Thoughts from Anthony Zietman. Incoming Editor in Chief of the Red Journal, Sue Yom, MD, PhD, hosts a podcast with Anthony Zietman, MD - his final episode as Editor in Chief. The conversation includes a discussion of the history of the journal, changes in scientific publishing, and memorable moments from Dr. Zietman's tenure.

Send us a text

The Story of SBRT. Dr. Sue Yom introduces new initiatives for the Red Journal under her editorship and discusses the origins, establishment, and future potential of stereotactic radiotherapy with Dr. Robert Timmerman.

Send us a text

Practical Radiation Oncology executive editor Sanford Meeks, PhD, hosts a conversation on the use of single-isocenter radiosurgery for multiple metastases. Dr. Meeks is joined by Richard Popple, PhD and John Fiveash, MD from the University of Alabama at Birmingham, as well as Stephen Tenn, PhD from the University of California, Los Angeles and Catherine Mercado, MD, from Orlando Health Cancer Institute. Dr. Meeks and guests discuss the changes in radiosurgery technology, features and differences of different radiosurgery systems, treatment planning procedures, and the clinical considerations when adopting these modalities.

Send us a text

Editor-in-Chief, Robert Amdur, MD, discusses three Practice Pearls from the most recent PROshot article: Adjuvant radiation halves the rate of ipsilateral breast recurrences at 10 and 15 years with minimal late toxicity in women with good-risk ductal carcinoma in situ; women with early-stage vulvar cancer and sentinel lymph node micrometastases (≤2 mm) can safely forgo ipsilateral completion lymph node dissection to reduce morbidity, but those with macrometastases cannot; and prophylactic cranial irradiation using hippocampal avoidance for SCLC helps preserve short-term memory.

Send us a text

Editor-in-Chief, Robert Amdur, MD, discusses a topic featured in the November/December issue of PRO, radiation therapy for femur metastases. Two letters in the issue (Recht et al. and Tseng et al.) debate the appropriate treatment regimen for radiation therapy to the intact femur. Dr. Amdur also references an editorial by Tseng et al., previously published in PRO, summarizing a clinical practice guideline for treatment of metastatic disease of the femur from the Musculoskeletal Tumor Society.

Send us a text

The latest podcast by Anthony Zietman, MD, Editor in Chief of the International Journal of Radiation Oncology, Biology, Physics focuses on: Personal reflections on life and Hodgkin Lymphoma.

Send us a text

Editor-in-Chief, Robert Amdur, MD, discusses an article from the September/October issue of PRO, "Sparing the Larynx and Hypopharynx with Radiotherapy for Squamous Cell Carcinoma of Unknown Primary Site and Predominant Adenopathy in Level IIA" and gives his five principles for deciding which mucosal sites to treat with an unknown primary.